Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 6
1981 9
1982 19
1983 19
1984 20
1985 48
1986 42
1987 55
1988 50
1989 65
1990 67
1991 79
1992 64
1993 45
1994 61
1995 68
1996 52
1997 52
1998 44
1999 36
2000 29
2001 33
2002 24
2003 21
2004 16
2005 18
2006 13
2007 12
2008 11
2009 16
2010 14
2011 8
2012 12
2013 16
2014 13
2015 13
2016 12
2017 8
2018 6
2019 5
2020 5
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

1,186 results
Results by year
Filters applied: . Clear all
Page 1
Calcium-channel blocking agents.
Leonard RG, Talbert RL. Leonard RG, et al. Clin Pharm. 1982 Jan-Feb;1(1):17-33. Clin Pharm. 1982. PMID: 6764159 Review.
Diltiazem's oral bioavailability is good (90% reaches systemic circulation), but there is significant interindividual variability between administered dose and resulting plasma concentration. Geriatric patients have delayed absorption and reduced clearance of diltiazem
Diltiazem's oral bioavailability is good (90% reaches systemic circulation), but there is significant interindividual variability bet
An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy.
Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. Burris JF, et al. JAMA. 1990 Mar 16;263(11):1507-12. JAMA. 1990. PMID: 2407872 Clinical Trial.
After a 4- to 6-week placebo run-in period, 297 qualifying patients were randomized to receive placebo, 1 of 4 doses of diltiazem SR monotherapy, 1 of 3 doses of hydrochlorothiazide monotherapy, or 1 of 12 possible combinations of diltiazem SR and hydrochlorothiazid …
After a 4- to 6-week placebo run-in period, 297 qualifying patients were randomized to receive placebo, 1 of 4 doses of diltiazem SR …
Antihypertensive safety and efficacy and physician and patient satisfaction: results from a phase 4 practice-based clinical experience trial with diltiazem LA.
Glasser SP. Glasser SP. Adv Ther. 2006 Mar-Apr;23(2):284-94. doi: 10.1007/BF02850134. Adv Ther. 2006. PMID: 16751161 Clinical Trial.
This study was undertaken to assess the safety and efficacy of a new long-acting formulation of diltiazem (DLA) (Cardizem LA; Biovail Pharmaceuticals, Inc., Bridgewater, NJ) in a large heterogeneous group of hypertensive patients, and to evaluate physician and patient trea …
This study was undertaken to assess the safety and efficacy of a new long-acting formulation of diltiazem (DLA) (Cardizem LA; Biovail …
Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research Group.
Boden WE, Scheldewaert R, Walters EG, Whitehead A, Coltart DJ, Santoni JP, Belgrave G, Starkey IR. Boden WE, et al. Am J Cardiol. 1995 Jun 1;75(16):1120-3. doi: 10.1016/s0002-9149(99)80742-5. Am J Cardiol. 1995. PMID: 7762497 Clinical Trial.
Although calcium antagonists have not been shown to alter post-AMI mortality, diltiazem has been shown to reduce recurrent nonfatal infarction and myocardial ischemia following non-Q-wave AMI. ...We have initiated a multicenter, randomized, placebo-controlled, double-blind …
Although calcium antagonists have not been shown to alter post-AMI mortality, diltiazem has been shown to reduce recurrent nonfatal i …
Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients.
Guan XF, Li DY, Yin WJ, Ding JJ, Zhou LY, Wang JL, Ma RR, Zuo XC. Guan XF, et al. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):55-62. doi: 10.1007/s13318-017-0425-y. Eur J Drug Metab Pharmacokinet. 2018. PMID: 28646274 Clinical Trial.
Several population pharmacokinetic (PopPK) models had been established for cyclosporine A and tacrolimus but no specific PopPK model was established for diltiazem. The aim of the study is to develop a PopPK model for diltiazem in renal transplant recipients and prov …
Several population pharmacokinetic (PopPK) models had been established for cyclosporine A and tacrolimus but no specific PopPK model was est …
Combined administration of diltiazem and nicardipine attenuates hypertensive responses to emergence and extubation.
Tsutsui T. Tsutsui T. J Neurosurg Anesthesiol. 2002 Apr;14(2):89-95. doi: 10.1097/00008506-200204000-00001. J Neurosurg Anesthesiol. 2002. PMID: 11907387 Clinical Trial.
Diltiazem and nicardipine, when injected as a mixture during anesthesia, reduce blood pressure in an additive manner without changing heart rate. ...Two patients in the treated SAH group exhibited tachycardia. The combined administration of diltiazem and nicardipine
Diltiazem and nicardipine, when injected as a mixture during anesthesia, reduce blood pressure in an additive manner without changing
Clinical utility of nifedipine and diltiazem plasma levels in patients with angina pectoris receiving monotherapy and combination treatment.
Goldberger J, Frishman WH. Goldberger J, et al. J Clin Pharmacol. 1989 Jul;29(7):628-34. doi: 10.1002/j.1552-4604.1989.tb03391.x. J Clin Pharmacol. 1989. PMID: 2760256 Clinical Trial.
The clinical utility of nifedipine and diltiazem blood levels in patients with angina pectoris receiving monotherapy (N = 14) and combination treatment (N = 9) were assessed in a placebo run-in, double blind, randomized, crossover study. Compared to placebo, diltiazem
The clinical utility of nifedipine and diltiazem blood levels in patients with angina pectoris receiving monotherapy (N = 14) and com …
A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery.
Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G, Frank DM, Borzak S. Tisdale JE, et al. Am Heart J. 1998 May;135(5 Pt 1):739-47. doi: 10.1016/s0002-8703(98)70031-6. Am Heart J. 1998. PMID: 9588402 Clinical Trial.
At 2 hours, the proportion of patients who achieved rate control was significantly higher in patients treated with diltiazem (75% vs 35%, p = 0.03). Similarly, at 6 hours, the response rate associated with diltiazem was higher than that in the digoxin group (85% vs …
At 2 hours, the proportion of patients who achieved rate control was significantly higher in patients treated with diltiazem (75% vs …
Clinical efficacy and safety of once-daily diltiazem in patients with stable angina pectoris switched from twice-daily diltiazem.
Savard D, Lenis J, Juneau M, Jacob C, Boulet AP. Savard D, et al. J Cardiovasc Pharmacol. 1995 Jul;26(1):85-9. doi: 10.1097/00005344-199507000-00014. J Cardiovasc Pharmacol. 1995. PMID: 7564371 Clinical Trial.
Patients with stable angina pectoris receiving twice-daily sustained-release (SR) diltiazem were switched to equivalent doses of once-daily controlled-delivery (CD) diltiazem or to diltiazem SR. ...A similar trend was observed in patients randomized to dil
Patients with stable angina pectoris receiving twice-daily sustained-release (SR) diltiazem were switched to equivalent doses of once …
Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets.
Emara LH, El-Ashmawy AA, Taha NF. Emara LH, et al. Pharm Dev Technol. 2018 Dec;23(10):1057-1066. doi: 10.1080/10837450.2017.1341523. Epub 2017 Jul 3. Pharm Dev Technol. 2018. PMID: 28604151 Clinical Trial.
The aim of this study was to prepare and evaluate in vitro and in vivo; Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets. ...
The aim of this study was to prepare and evaluate in vitro and in vivo; Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tab …
1,186 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page